FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279913520> ?p ?o ?g. }

• W2279913520 endingPage "39" @default.
• W2279913520 startingPage "33" @default.
• W2279913520 abstract "Due to a lack of effective screening or prevention protocol for epithelial ovarian cancer (EOC), there is a critical unmet need to develop therapeutic interventions for EOC treatment. EOC metastasis is unique. Initial dissemination is not primarily hematogenous, yet is facilitated through shedding of primary tumor cells into the peritoneal fluid and accumulating ascites. Increasingly, isolated patient spheroids point to a clinical role for spheroids in EOC metastasis. EOC spheroids are highly invasive structures that disseminate upon peritoneal mesothelium, and visceral tissues including liver and omentum. Selection for this subset of chemoresistant EOC cells could influence disease progression and/or recurrence. Thus, targeting spheroid integrity/structure may improve the chemotherapeutic responsiveness of EOC. We discovered a critical role for mammalian Diaphanous (mDia)-related formin-2 in maintaining EOC spheroid structure. Both mDia2 and the related mDia1 regulate F-actin networks critical to maintain cell-cell contacts and the integrity of multi-cellular epithelial sheets. We investigated if mDia2 functional inhibition via a small molecule inhibitor SMIFH2 combined with chemotherapeutics, such as taxol and cisplatin, inhibits the viability of EOC monolayers and clinically relevant spheroids. SMIFH2-mediated mDia formin inhibition significantly reduced both ES2 and Skov3 EOC monolayer viability while spheroid viability was minimally impacted only at the highest concentrations. Combining either cisplatin or taxol with SMIFH2 did not significantly enhance the effects of either drug alone in ES2 monolayers, while Skov3 monolayers treated with taxol or cisplatin and SMIFH2 showed significant additive inhibition of viability. ES2 spheroids were highly responsive with clear additive anti-viability effects with dual taxol or cisplatin when combined with SMIFH2 treatments. While combined taxol with SMIFH2 in spheroids showed an additive effect relative to single treatments, Skov3 spheroids showed no additive effects from combined cisplatin and SMIFH2 treatments. Our data indicate that mDia formin inhibition combined with taxol to drive enhanced and/or additive anti-viability effects targeting 3D EOC structures, including ES2 and Skov3 spheroids. Combined mDia formin inhibition with cisplatin may be most effective in EOC spheroids where cisplatin sensitivity is retained at moderate levels, such as ES2 cells." @default.
• W2279913520 created "2016-06-24" @default.
• W2279913520 creator A5007409645 @default.
• W2279913520 creator A5050319444 @default.
• W2279913520 creator A5060809418 @default.
• W2279913520 creator A5062559387 @default.
• W2279913520 creator A5065548117 @default.
• W2279913520 date "2016-03-01" @default.
• W2279913520 modified "2023-09-26" @default.
• W2279913520 title "SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids" @default.
• W2279913520 cites W1893802841 @default.
• W2279913520 cites W1920390126 @default.
• W2279913520 cites W1982995182 @default.
• W2279913520 cites W1991242976 @default.
• W2279913520 cites W1994659121 @default.
• W2279913520 cites W1996066317 @default.
• W2279913520 cites W1996604878 @default.
• W2279913520 cites W2005424301 @default.
• W2279913520 cites W2007554905 @default.
• W2279913520 cites W2008922789 @default.
• W2279913520 cites W2016727199 @default.
• W2279913520 cites W2027795380 @default.
• W2279913520 cites W2032169282 @default.
• W2279913520 cites W2033575518 @default.
• W2279913520 cites W2046913436 @default.
• W2279913520 cites W2047311008 @default.
• W2279913520 cites W2052587164 @default.
• W2279913520 cites W2072400772 @default.
• W2279913520 cites W2078354424 @default.
• W2279913520 cites W2087127543 @default.
• W2279913520 cites W2090512174 @default.
• W2279913520 cites W2093585643 @default.
• W2279913520 cites W2096243643 @default.
• W2279913520 cites W2102640342 @default.
• W2279913520 cites W2110048188 @default.
• W2279913520 cites W2113586104 @default.
• W2279913520 cites W2137750805 @default.
• W2279913520 cites W2149249471 @default.
• W2279913520 cites W2157197884 @default.
• W2279913520 cites W2159510040 @default.
• W2279913520 cites W2159935881 @default.
• W2279913520 doi "https://doi.org/10.1016/j.bbrc.2016.02.049" @default.
• W2279913520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26898799" @default.
• W2279913520 hasPublicationYear "2016" @default.
• W2279913520 type Work @default.
• W2279913520 sameAs 2279913520 @default.
• W2279913520 citedByCount "8" @default.
• W2279913520 countsByYear W22799135202018 @default.
• W2279913520 countsByYear W22799135202019 @default.
• W2279913520 countsByYear W22799135202020 @default.
• W2279913520 countsByYear W22799135202021 @default.
• W2279913520 countsByYear W22799135202022 @default.
• W2279913520 crossrefType "journal-article" @default.
• W2279913520 hasAuthorship W2279913520A5007409645 @default.
• W2279913520 hasAuthorship W2279913520A5050319444 @default.
• W2279913520 hasAuthorship W2279913520A5060809418 @default.
• W2279913520 hasAuthorship W2279913520A5062559387 @default.
• W2279913520 hasAuthorship W2279913520A5065548117 @default.
• W2279913520 hasConcept C121608353 @default.
• W2279913520 hasConcept C126322002 @default.
• W2279913520 hasConcept C142669718 @default.
• W2279913520 hasConcept C1491633281 @default.
• W2279913520 hasConcept C175369904 @default.
• W2279913520 hasConcept C2776694085 @default.
• W2279913520 hasConcept C2778239845 @default.
• W2279913520 hasConcept C2779013556 @default.
• W2279913520 hasConcept C2780427987 @default.
• W2279913520 hasConcept C2993400109 @default.
• W2279913520 hasConcept C502942594 @default.
• W2279913520 hasConcept C53195969 @default.
• W2279913520 hasConcept C53227056 @default.
• W2279913520 hasConcept C54355233 @default.
• W2279913520 hasConcept C55493867 @default.
• W2279913520 hasConcept C71924100 @default.
• W2279913520 hasConcept C81885089 @default.
• W2279913520 hasConcept C86803240 @default.
• W2279913520 hasConceptScore W2279913520C121608353 @default.
• W2279913520 hasConceptScore W2279913520C126322002 @default.
• W2279913520 hasConceptScore W2279913520C142669718 @default.
• W2279913520 hasConceptScore W2279913520C1491633281 @default.
• W2279913520 hasConceptScore W2279913520C175369904 @default.
• W2279913520 hasConceptScore W2279913520C2776694085 @default.
• W2279913520 hasConceptScore W2279913520C2778239845 @default.
• W2279913520 hasConceptScore W2279913520C2779013556 @default.
• W2279913520 hasConceptScore W2279913520C2780427987 @default.
• W2279913520 hasConceptScore W2279913520C2993400109 @default.
• W2279913520 hasConceptScore W2279913520C502942594 @default.
• W2279913520 hasConceptScore W2279913520C53195969 @default.
• W2279913520 hasConceptScore W2279913520C53227056 @default.
• W2279913520 hasConceptScore W2279913520C54355233 @default.
• W2279913520 hasConceptScore W2279913520C55493867 @default.
• W2279913520 hasConceptScore W2279913520C71924100 @default.
• W2279913520 hasConceptScore W2279913520C81885089 @default.
• W2279913520 hasConceptScore W2279913520C86803240 @default.
• W2279913520 hasFunder F4320337504 @default.
• W2279913520 hasIssue "1" @default.
• W2279913520 hasLocation W22799135201 @default.
• W2279913520 hasLocation W22799135202 @default.

• next